Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Aftin-4 (HB3741)
Description:Roscovitine-related purine with no activity on CDKs. Roscovitine control. Increases Aβ42 production.
Purity:>98%
Aftin-5 (HB3742)
Description:Roscovitine-related purine with no activity on CDKs. Roscovitine control. Increases Aβ42 production.
Purity:>98%
Agistatin D (HB3745)
Description:Cholesterol biosynthesis inhibitor. Analog of agistatin A.
Purity:>98%
AICAR (HB2152)
Description:AMPK activator. Promotes osteogenic differentiation of bone marrow-derived MSCs.
Purity:>99%
- Description:
Immunostimulant. Natural killer T cell stimulator.
Purity:>96%